Von Eschenbach a “misguided choice” for FDA, House members write to HHS Secretary Leavitt. Conflicts inadequately addressed, they said.
Capitol Hill: With money tight, support for 2015 goal is symbolic.
Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.
NCI selects nanotech centers for funding.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final









